DK3220939T3 - Homodimer-peptid til behandling af diabetes og relaterede sygdomme - Google Patents

Homodimer-peptid til behandling af diabetes og relaterede sygdomme Download PDF

Info

Publication number
DK3220939T3
DK3220939T3 DK15795157.5T DK15795157T DK3220939T3 DK 3220939 T3 DK3220939 T3 DK 3220939T3 DK 15795157 T DK15795157 T DK 15795157T DK 3220939 T3 DK3220939 T3 DK 3220939T3
Authority
DK
Denmark
Prior art keywords
diabetes
treatment
related diseases
homodimer
peptide
Prior art date
Application number
DK15795157.5T
Other languages
Danish (da)
English (en)
Inventor
Arpi Rogers
Original Assignee
Arpi Rogers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arpi Rogers filed Critical Arpi Rogers
Application granted granted Critical
Publication of DK3220939T3 publication Critical patent/DK3220939T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK15795157.5T 2014-11-18 2015-11-16 Homodimer-peptid til behandling af diabetes og relaterede sygdomme DK3220939T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1420445.7A GB2532426B (en) 2014-11-18 2014-11-18 Therapeutic homodimer and uses thereof
PCT/EP2015/076712 WO2016079066A1 (en) 2014-11-18 2015-11-16 Therapeutic homodimer and uses thereof

Publications (1)

Publication Number Publication Date
DK3220939T3 true DK3220939T3 (da) 2021-08-30

Family

ID=52248504

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15795157.5T DK3220939T3 (da) 2014-11-18 2015-11-16 Homodimer-peptid til behandling af diabetes og relaterede sygdomme

Country Status (19)

Country Link
US (2) US20180015136A1 (enExample)
EP (1) EP3220939B1 (enExample)
JP (1) JP6693969B2 (enExample)
KR (1) KR20170083064A (enExample)
CN (1) CN107206048B (enExample)
AU (1) AU2015348673B2 (enExample)
BR (1) BR112017010346A2 (enExample)
CA (1) CA2967140C (enExample)
CY (1) CY1124859T1 (enExample)
DK (1) DK3220939T3 (enExample)
EA (1) EA034876B1 (enExample)
ES (1) ES2886001T3 (enExample)
GB (1) GB2532426B (enExample)
IL (1) IL252349B (enExample)
MA (1) MA40969A (enExample)
MX (1) MX392248B (enExample)
SG (1) SG11201703757PA (enExample)
WO (1) WO2016079066A1 (enExample)
ZA (1) ZA201703580B (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0516527D0 (en) * 2005-08-11 2005-09-21 Arpi Matossian Rogers Peptides
DK2594591T3 (en) * 2005-08-11 2018-07-30 Matossian Rogers Arpi TCR-V-BETA RELATED PEPTIDES FOR TREATMENT AND DIAGNOSIS OF AUTOIMMUNE DISEASE

Also Published As

Publication number Publication date
IL252349B (en) 2022-02-01
MA40969A (fr) 2021-04-28
CN107206048B (zh) 2021-02-26
EP3220939A1 (en) 2017-09-27
BR112017010346A2 (pt) 2018-05-15
CA2967140C (en) 2021-09-21
AU2015348673A1 (en) 2017-06-01
CA2967140A1 (en) 2016-05-26
HK1223287A1 (zh) 2017-07-28
GB201420445D0 (en) 2014-12-31
ZA201703580B (en) 2018-08-29
ES2886001T3 (es) 2021-12-16
GB2532426A (en) 2016-05-25
WO2016079066A1 (en) 2016-05-26
MX2017006278A (es) 2017-10-24
CN107206048A (zh) 2017-09-26
KR20170083064A (ko) 2017-07-17
GB2532426B (en) 2016-11-02
EP3220939B1 (en) 2021-06-30
IL252349A0 (en) 2017-07-31
EA201791103A1 (ru) 2017-09-29
AU2015348673B2 (en) 2019-01-03
NZ731655A (en) 2020-09-25
SG11201703757PA (en) 2017-06-29
CY1124859T1 (el) 2022-11-25
MX392248B (es) 2025-03-24
US20210060118A1 (en) 2021-03-04
JP6693969B2 (ja) 2020-05-13
EA034876B1 (ru) 2020-04-01
US20180015136A1 (en) 2018-01-18
JP2018500386A (ja) 2018-01-11

Similar Documents

Publication Publication Date Title
IL258402A (en) Electroporation for obesity or diabetes treatment
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3280441T3 (da) Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3259597T3 (da) Pvrig-polypeptider og fremgangsmåder til behandling
DK3227262T3 (da) Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling
DK3402888T3 (da) Middel og fremgangsmåder til behandling af hbv
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3201336T3 (da) Fremgangsmåder til ekstrahering og oprensning af ikke-denaturerede proteiner
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3442580T3 (da) Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme
DK3148579T3 (da) Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
DK3116911T3 (da) Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
DK3096798T3 (da) Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3102189T3 (da) Sammensætning og fremgangsmåde til at fremme søvn
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3303339T3 (da) Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3094640T3 (da) Fremgangsmåder til steril kromatografi og fremstilling
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme